Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information


Montreal, CAN
141, Président-Kennedy ave.
Suite SB-5100, Quebec,
Montreal, H2X 1Y4, CAN


Chairman of Board of Directors
President and CEO
Board of Directors
Board of Directors
Board of Directors
Board of Directors & CFO
Director of Intellectual Property
Director of Preclinical Drug Development
Show All People



Alethia BioTherapeutics

Alethia BioTherapeutics, Inc., a biotechnology company, engages in the discovery and development of monoclonal antibody-based therapeutics focusing on the cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and on cancer-induced bone loss. Its products include Isogranulatimide, a G2 checkpoint inhibitor, which potentiates the response to several DNA-damaging chemotherapeutic agents; sCLU, a heterodimeric disulphide-linked glycoprotein of 449 amino acids, the over-expression of which is observed in various malignancies, including prostate, bladder, kidney, breast, colon, and lung tumors; AB-0447, an antigen that is expressed at the surface of ovarian cancer epithelial cells in greater than eighty five percent of malignant tumors; and AB-0440, a cell-surface protease-like protein, whose expression is stimulated early in osteoclast differentiation in response to RANK ligand. The company was founded in 2002 and is based in Montreal, Canada.

Recent Milestones




  1. Alethia Biotherapeutics Brings Home $9.2M Series A ( [edit]
  2. Alethia Biotherapeutics Closes a $4.7 Million Financing to Advance its Bone Antiresorptive Program ( [edit]
Edit This Page
Last Edited 3/28/14

Revision History RSS Picture


Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API


Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy